- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05176704
Development and Validation of a Novel Functional Eye-Tracking Software Application for Alzheimer's Disease
This study aims to develop and validate a sensitive and non-invasive eye-tracking software application.
This study will obtain participant responses to brief cognitive tests designed to evaluate several key functions known to be affected by Alzheimer's Disease and non-invasive eye movement measurements in response to visually presented stimuli during specifically designed eye-tracking tests. The study data will be used to develop machine learning algorithms and validate a software application intended to track the progressive component of Alzheimer's Disease and associated cognitive changes.
Study Overview
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Nancy Mugisha
- Phone Number: 3451 (514) 761-6131
- Email: nancy.mugisha.comtl@ssss.gouv.qc.ca
Study Locations
-
-
Quebec
-
Montréal, Quebec, Canada, H4H 1R3
- Recruiting
- The Douglas Research Centre
-
Contact:
- Nancy Mugisha
- Phone Number: 3451 (514) 761-6131
- Email: nancy.mugisha.comtl@ssss.gouv.qc.ca
-
Principal Investigator:
- Simon Ducharme
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
For all participants:
- Able to provide informed consent
- Aged 18 years or older at the time of enrollment
- Able to read in either French or English
- Visual acuity of 20/100 in at least one eye (corrective glasses, contact lenses, surgery etc. are permitted)
For patients only:
- Confirmed diagnosis of AD based on the NIAAA diagnostic criteria of probable AD
- Having undergone a full neuropsychological evaluation within the last 6 months or having a planned full neuropsychological evaluation within the next 6 months.
- AD diagnoses supported by FDG-PET scan or amyloid biomarkers (CSF or amyloid PET)
Exclusion Criteria:
For AD participants:
- Diagnosed with one of the following dementia subtypes: Fronto-temporal dementia, Lewy-body dementia, or Creutzfeldt-Jakob disease.
- Incapacity to provide informed consent or inability to adequately understand the task instructions.
For all participants:
- Evidence or medical history of psychiatric issues, which are known to also affect movements and oculomotor control.
- Presence of comorbid neurological conditions to avoid eye movement anomaly confounds (strabismus, cranial nerve palsy, stroke-causing hemianopsia).
- Diagnosis of macular edema or other pre-existing ocular conditions (e.g., glaucoma, cataracts) that would prevent from performing the eye movement assessments.
- Unstable medication use: recent (less than one month from enrollment) start of, change of dose, or irregular use of, new prescription drugs known to have an effect on ocular motor visual function, such as benzodiazepines, antipsychotics and anticonvulsants. Occasional use of benzodiazepines for medical procedures is permitted, at the investigator's discretion, but should not occur within a short time period of an eye movement assessment.
- Diagnosed with an active substance use disorder.
- History of stroke.
- Recent traumatic brain injury (within the last 6 months).
For healthy controls only:
- Evidence or history of significant neurodegenerative disorder affecting brain function (e.g., MS, PD, ALS, Non-AD Dementia)
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Cross-Sectional
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
CDR = 0.5
50 Alzheimer's Disease (AD) patients including predominant AD with mixed vascular and MCI due to AD based on their CDR score.
Questionable/very mild dementia (CDR = 0.5)
|
Eye-tracking technology and algorithms used to successfully capture and track eye movements using an electronic tablet and the embedded camera of the device.
|
CDR = 1
50 Alzheimer's Disease (AD) patients including predominant AD with mixed vascular and MCI due to AD based on their CDR score.
Mild dementia/MCI (CDR = 1)
|
Eye-tracking technology and algorithms used to successfully capture and track eye movements using an electronic tablet and the embedded camera of the device.
|
CDR = 2
50 Alzheimer's Disease (AD) patients including predominant AD with mixed vascular and MCI due to AD based on their CDR score.
Moderate dementia (CDR = 2)
|
Eye-tracking technology and algorithms used to successfully capture and track eye movements using an electronic tablet and the embedded camera of the device.
|
CDR = 3
50 Alzheimer's Disease (AD) patients including predominant AD with mixed vascular and MCI due to AD based on their CDR score.
Severe dementia (CDR = 3)
|
Eye-tracking technology and algorithms used to successfully capture and track eye movements using an electronic tablet and the embedded camera of the device.
|
Healthy Control
50 Participant with no evidence or history of significant neurodegenerative disorder affecting brain function.
|
Eye-tracking technology and algorithms used to successfully capture and track eye movements using an electronic tablet and the embedded camera of the device.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical Dementia Rating (CDR) score, one time, at the day of enrollment.
Time Frame: Baseline
|
The Clinical Dementia Rating (CDR) is a global rating scale for staging patients diagnosed with Alzheimer disease and other dementias and monitoring changes in the level of there disabilities over time.
The CDR scale is a 0-3 point numeric scale (0.5 unit increments) derived from clinician rating of cognition and daily function in the domains of memory, orientation, judgment and problem solving, community affairs, home and hobbies and personal care.
|
Baseline
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The Montreal Cognitive Assessment (MoCA) score, one time, at the day of enrollment.
Time Frame: Baseline
|
The Montreal Cognitive Assessment (MoCA) is a brief 30-question cognitive screening test designed to assist Health Professionals in the detection of mild cognitive impairment and Alzheimer's disease. It assesses different cognitive domains: attention and concentration, executive functions, memory, language, visuoconstructional skills, conceptual thinking, calculations, and orientation. Scores on the MoCA range from zero to 30, with a score of 26 and higher generally considered normal. |
Baseline
|
The Mini-Mental State Exam (MMSE) score, one time, at the day of enrollment.
Time Frame: Baseline
|
The Mini-Mental State Exam (MMSE) is a widely used test of cognitive function among the elderly, it includes tests of orientation, attention, memory, language and visual-spatial skills.
It consists of a series of questions and tests that can be used by clinicians to help diagnose dementia and to help assess its progression and severity.
|
Baseline
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ETNA-AD
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alzheimer's Disease
-
University of Southern CaliforniaAlzheimer's Therapeutic Research Institute; American Heart Association; Schaeffer...RecruitingDementia | Alzheimer Disease | Prodromal Alzheimer's Disease | Preclinical Alzheimer's DiseaseUnited States
-
University of Southern CaliforniaNational Institute on Aging (NIA); Alzheimer's Therapeutic Research Institute; Brigham and Women's Hospital and other collaboratorsActive, not recruitingDementia | Alzheimer Disease | Prodromal Alzheimer's Disease | Preclinical Alzheimer's DiseaseUnited States
-
Novoic LimitedRecruitingAlzheimer Disease | Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Alzheimer's Disease (Incl Subtypes) | Preclinical Alzheimer's DiseaseUnited States
-
Novoic LimitedRecruitingAlzheimer Disease | Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Alzheimer's Disease (Incl Subtypes) | Preclinical Alzheimer's DiseaseUnited Kingdom
-
Novoic LimitedCompletedAlzheimer Disease | Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Alzheimer's Disease (Incl Subtypes) | Preclinical Alzheimer's DiseaseUnited States
-
Novoic LimitedRecruitingAlzheimer Disease | Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Alzheimer's Disease (Incl Subtypes) | Preclinical Alzheimer's DiseaseUnited Kingdom
-
Novoic LimitedCompletedAlzheimer Disease | Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Alzheimer's Disease (Incl Subtypes) | Preclinical Alzheimer's DiseaseUnited Kingdom
-
Novoic LimitedRecruitingAlzheimer Disease | Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Alzheimer's Disease (Incl Subtypes) | Preclinical Alzheimer's Disease | Normal CognitionUnited States
-
University Hospital, BordeauxMinistry for Health and Solidarity, FranceCompletedAlzheimer's Disease (AD) | Alzheimer's Disease (AD) Related DisordersFrance
-
University of Colorado, DenverNational Institute on Aging (NIA)Active, not recruitingSuspected Typical Alzheimer's Disease (AD) | Suspected Atypical Alzheimer's Disease (AD)United States
Clinical Trials on Eye-Tracking
-
Institut National de la Santé Et de la Recherche...CompletedHealthy | Parkinson Disease | DystoniaFrance
-
Innodem NeurosciencesSyneos HealthRecruiting
-
Innodem NeurosciencesNovartis PharmaceuticalsRecruitingMultiple SclerosisCanada
-
McGill UniversityInnodem NeurosciencesRecruitingClinically Isolated Syndrome | Relapsing Remitting Multiple SclerosisCanada
-
University Hospitals Cleveland Medical CenterRecruitingBipolar DisorderUnited States
-
Innodem NeurosciencesSuspendedNeurological DisordersCanada
-
Instituto Universitario de Oftalmobiología Aplicada...Hospital del Río Hortega; Hospital Clínico Universitario de ValladolidCompletedMultiple Sclerosis | Eye Abnormalities | Parkinson Disease | Ataxia, Cerebellar | Injury BrainSpain
-
Innodem NeurosciencesNot yet recruiting
-
Innodem NeurosciencesRecruitingMultiple SclerosisCanada
-
Innodem NeurosciencesRecruitingCancer-related Cognitive ImpairmentCanada